Beijing Hotgen Biotech Co Ltd
Beijing Hotgen Biotech Co., Ltd. engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine. It offers public safety solutions such as drug tasting, customs disease control, bioterrorism and food safety solutions. The company also provides clinical diagnostics and product solutions, inclu… Read more
Beijing Hotgen Biotech Co Ltd (688068) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.001x
Based on the latest financial reports, Beijing Hotgen Biotech Co Ltd (688068) has a cash flow conversion efficiency ratio of 0.001x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥3.05 Million) by net assets (CN¥2.93 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Beijing Hotgen Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Beijing Hotgen Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Beijing Hotgen Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beijing Hotgen Biotech Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Renishaw plc
PINK:RNSHF
|
0.040x |
|
Gemadept Corp
VN:GMD
|
-0.008x |
|
AKSO HEALTH GR. (SPADR)/3
F:8HX
|
N/A |
|
Proximus PLC
PINK:BGAOF
|
0.075x |
|
BIRD CONSTRUCTION
F:6LT
|
N/A |
|
Aarti Industries Limited
NSE:AARTIIND
|
0.098x |
|
Integrated Cannabis Company Inc
PINK:CRPGF
|
0.000x |
|
Eyebright Medical Technology Beijing Co Ltd
SHG:688050
|
0.026x |
Annual Cash Flow Conversion Efficiency for Beijing Hotgen Biotech Co Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Beijing Hotgen Biotech Co Ltd from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥3.07 Billion | CN¥-37.16 Million | -0.012x | -59.91% |
| 2023-12-31 | CN¥3.36 Billion | CN¥-25.39 Million | -0.008x | -102.59% |
| 2022-12-31 | CN¥3.35 Billion | CN¥978.75 Million | 0.292x | -68.28% |
| 2021-12-31 | CN¥2.87 Billion | CN¥2.64 Billion | 0.920x | +317.43% |
| 2020-12-31 | CN¥746.79 Million | CN¥164.62 Million | 0.220x | +638.85% |
| 2019-12-31 | CN¥649.30 Million | CN¥19.37 Million | 0.030x | -88.59% |
| 2018-12-31 | CN¥210.44 Million | CN¥55.04 Million | 0.262x | +84.21% |
| 2017-12-31 | CN¥161.65 Million | CN¥22.95 Million | 0.142x | -59.17% |
| 2016-12-31 | CN¥130.98 Million | CN¥45.54 Million | 0.348x | -- |